Mineralys Therapeutics (MLYS) Change in Interest Receivables (2023 - 2026)
Mineralys Therapeutics' (MLYS) quarterly Change in Interest Receivables came in at -$289000.0 in Q1 2026, down 455.77% year-on-year from $81232.4 in Q1 2025, and down 259.67% quarter-over-quarter from $181000.0 in Q4 2025.
Mineralys Therapeutics (MLYS) Change in Interest Receivables (2023 - 2026) Analysis & Trends
Mineralys Therapeutics has disclosed Change in Interest Receivables across 4 years of filings, most recently posting -$289000.0 for Q1 2026.
- Change in Interest Receivables for Q1 2026 came in at -$289000.0, down 455.77% year-over-year; the trailing twelve-month figure through Mar 2026 was -$71000.0 (up 80.11% YoY), and the FY2025 annual result was $166000.0, up 139.15% from the prior year.
- Change in Interest Receivables came in at -$289000.0 for Q1 2026 at Mineralys Therapeutics, down from $181000.0 in the prior quarter.
- In the past five years, Change in Interest Receivables ranged from a high of $270000.0 in Q1 2023 to a low of -$300000.0 in Q4 2023.
- The 4-year median for Change in Interest Receivables is -$23000.0 (2024), against an average of -$14769.2.
- Across the five-year window, Change in Interest Receivables soared 284.69% in 2025 and slumped 455.77% in 2026, its largest moves.
- Mineralys Therapeutics' Change in Interest Receivables stood at -$300000.0 in 2023, then surged by 67.33% to -$98000.0 in 2024, then jumped by 284.69% to $181000.0 in 2025, then sank by 259.67% to -$289000.0 in 2026.
- The last three Change in Interest Receivables figures came in at -$289000.0 (Q1 2026), $181000.0 (Q4 2025), and -$10000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Interest Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Mineralys Therapeutics | 1.95 Bn | 1.95 Bn | - | -289,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -289,000.00 |
| Dec 31, 2025 | 181,000.00 |
| Sep 30, 2025 | -10,000.00 |
| Jun 30, 2025 | 47,000.00 |
| Mar 31, 2025 | -52,000.00 |
| Dec 31, 2024 | -98,000.00 |
| Sep 30, 2024 | -23,000.00 |
| Jun 30, 2024 | -184,000.00 |
| Mar 31, 2024 | -119,000.00 |
| Dec 31, 2023 | -300,000.00 |
| Sep 30, 2023 | 219,000.00 |
| Jun 30, 2023 | 166,000.00 |
| Mar 31, 2023 | 270,000.00 |